Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
08
03
2018
accepted:
20
04
2018
revised:
12
04
2018
pubmed:
10
8
2018
medline:
23
1
2020
entrez:
10
8
2018
Statut:
ppublish
Résumé
In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2014 changes to the original NIH cGVHD severity scoring criteria has not been reported. In this study, 284 patients, prospectively enrolled on the National Cancer Institute's cross-sectional cGVHD natural history study, were scored using the 2005 NIH cGVHD criteria and then rescored according to the 2014 modifications. In comparing the two criteria, 2014 cGVHD global severity scoring resulted in a tendency toward being categorized as milder scores (75 vs. 72% of severe score per 2014, p = 0.0009), with a statistically significant shift in NIH liver and lung scores toward milder categories (p < 0.0001). 2005 and 2014 NIH global severity scores showed a significant association with reduced grip strength (p < 0.0001), reduced joint range of motion (p = 0.0003), and the subspecialist evaluation score (p < 0.0001). Poor survival prediction of the severe NIH lung score is also retained in the new criteria (p = 0.0012). These findings support the use of 2014 cGVHD scoring criteria in continuous efforts to develop better classification systems.
Identifiants
pubmed: 30089900
doi: 10.1038/s41409-018-0224-3
pii: 10.1038/s41409-018-0224-3
pmc: PMC8268758
mid: NIHMS1707290
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-84Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC011743
Pays : United States
Références
Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63
pubmed: 24447907
Biol Blood Marrow Transplant. 2002;8(8):444-52
pubmed: 12234170
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Biol Blood Marrow Transplant. 2011 Feb;17(2):167-75
pubmed: 20691801
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Biol Blood Marrow Transplant. 2010 Jan;16(1):53-61
pubmed: 20053332
Bone Marrow Transplant. 2010 Apr;45(4):762-9
pubmed: 19784078
Bone Marrow Transplant. 2016 Oct;51(10):1350-1353
pubmed: 27214071
Biol Blood Marrow Transplant. 2013 Jun;19(6):967-72
pubmed: 23542686
Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33
pubmed: 12720215
Crit Care. 2004 Jun;8(3):196-9
pubmed: 15153238
J Clin Oncol. 2010 Feb 20;28(6):1011-6
pubmed: 20065176
Croat Med J. 2016 Feb;57(1):16-28
pubmed: 26935611
Bone Marrow Transplant. 1997 Feb;19(4):357-68
pubmed: 9051246
Bone Marrow Transplant. 2006 Aug;38(4):305-10
pubmed: 16819438
Biol Blood Marrow Transplant. 2016 Apr;22(4):752-758
pubmed: 26751003
Biol Blood Marrow Transplant. 2010 Dec;16(12):1707-17
pubmed: 20541028
Bone Marrow Transplant. 2017 Oct;52(10):1361-1366
pubmed: 28346419
Haematologica. 2017 Apr;102(4):614-625
pubmed: 28232372
Biol Blood Marrow Transplant. 2013 Apr;19(4):632-9
pubmed: 23340040
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383